Here is Why Edwards Lifesciences Corporation (EW) Looks Attractive

Edwards Lifesciences Corporation (NYSE:EW) is one of the 10 best healthcare equipment stocks to buy according to hedge funds.

On February 11, Richard Newitter from Truist Financial reduced the price target on Edwards Lifesciences Corporation (NYSE:EW) from $92 to $89. The analyst reaffirmed his Hold rating on the stock that offers a revised upside potential of more than 11%.

Newitter reflected favorably on the company’s fourth quarter revenue figures, which were higher than expected because of a double-digit growth in TAVR. However, the topline growth did not translate into higher profits.

On February 11, David Roman from Goldman Sachs reiterated his Buy rating on Edwards Lifesciences Corporation (NYSE:EW). The analyst lowered the target price from $108 to $95, which still yields a revised upside potential in the high teens. Roman maintained his bullish stance on the stock based on various upside drivers that are expected to play out during the coming year.

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company that offers patient-focused medical products and technologies to cure critical cardiovascular diseases. It also offers critical care monitoring services along with transcatheter heart valve repair & replacement products. Its surgical structural heart solutions include INSPIRIS aortic surgical valve, INSPIRIS RESILIA aortic valve, KONECT RESILIA, and MITRIS RESILIA valve.

While we acknowledge the potential of EW as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

Disclosure: None. This article is originally published at Insider Monkey.